REZOLUTE, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REZOLUTE, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $2.69M.
- REZOLUTE, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $0.00.
- REZOLUTE, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $0.00.
- REZOLUTE, INC. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $41.00M.
- REZOLUTE, INC. stock issued during period, value, new issues for fiscal 2021 was $41.00M.
- REZOLUTE, INC. stock issued during period, value, new issues for fiscal 2018 was $4.44M, a 62.81% decline from fiscal 2017.
- REZOLUTE, INC. stock issued during period, value, new issues for fiscal 2017 was $11.94M, a 284.33% increase from fiscal 2016.
- REZOLUTE, INC. stock issued during period, value, new issues for fiscal 2016 was $3.11M, a 34.85% decline from fiscal 2015.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2021-09-30 | $2.69M 10-Q · filed 2022-11-09 | $43.69M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-15 | $41.00M 10-K · filed 2021-09-15 |
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-12 | |
| 2020-12-31 | $41.00M 10-Q · filed 2022-02-09 | |
| 2019-03-31 | $25.00M 10-Q · filed 2019-05-10 | |
| 2018-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-10 | $4.44M 10-K · filed 2019-09-10 |
| 2018-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-15 | $7.98M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-14 | $12.48M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-09-30 | $4.44M 10-Q · filed 2019-05-10 | $14.77M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-06-30 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-15 | $11.94M 10-K · filed 2018-10-15 |
| 2017-03-31 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | |
| 2016-12-31 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-02 | |
| 2016-09-30 | $1.61M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $3.11M 10-K · filed 2017-09-22 | |
| 2015-06-30 | $480.24K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $4.77M 10-K · filed 2016-09-28 |
| 2015-03-31 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | |
| 2014-06-30 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28 | $3.48M 10-K · filed 2015-09-28 |
| 2012-06-30 | $18.50K 10-Q · filed 2013-02-14 | |
| 2011-12-31 | $0.00 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |